Recursion Aligns With FDA On Phase 3 Trial Design For FAP Drug REC-4881; Stock Up
Recursion Pharmaceuticals (RXRX) aligned with the FDA on the Phase 3 trial design for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). The trial, expected to start in late 2027, will assess composite event-free survival as the primary endpoint. REC-4881 has shown a 47% median reduction in total polyp burden in Phase 1b/2 trials. RXRX shares were up 4.41% in premarket trading.
How this was made

The 30-second read
Why it matters
By agreeing on a composite event-free survival primary endpoint that counts clinically meaningful adenoma removals plus other events, the FDA alignment reduces trial-design risk and clarifies what constitutes success for registrational evaluation.
Market read
Traders can reassess REC-4881’s regulatory de-risking and timeline, but the next major inflection (Phase 3 start and later readout) is still in the future.
What to watch
The dosing schedule depends on ongoing TUPELO trial results, so uncertainty remains around the final regimen and how it translates to the Phase 3 endpoint.
Background
REC-4881 is an investigational oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP), a condition with no approved pharmacologic therapies and ongoing surveillance needs after colectomy.
Ticker impact
Recursion says it aligned with the FDA on REC-4881 Phase 3 registrational trial design, including a composite event-free survival endpoint.
Likely upward bias as traders price reduced regulatory uncertainty and a clearer path to a future registrational trial start.
The article discloses a specific FDA alignment on primary endpoint construction and trial framework, plus an expected Phase 3 start window in 2H 2027.
Market effects
Reinforces investor focus on MEK-pathway oncology and GI polyp prevention programs with FDA-agreed endpoints.
Limited direct regional spillover; primarily affects US small/mid-cap biotech sentiment.
Modest global relevance as FAP is rare and the catalyst is FDA-specific trial design.
Counterpoint
Endpoint alignment does not guarantee efficacy; traders may still discount the Phase 3 probability given the long timeline to 2H 2027 initiation.
Key entities
- companyRecursion Pharmaceuticals, Inc.
Sponsor of REC-4881 and the party reaching FDA alignment on Phase 3 trial design.
- drugREC-4881
Investigational oral MEK1/2 inhibitor being evaluated in FAP.
- regulatorU.S. Food and Drug Administration (FDA)
Aligned on the registrational Phase 3 trial design and primary endpoint definition.



